TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients

Breast Cancer Research and Treatment

Volumn 132, Issue 1, 2012, Pages 225-234

  Hertel, Pernille Braemer ^a,b,j   Tu, Dongsheng ^c   Ejlertsen, Bent ^b,d   Jensen, Maj Britt ^d   Balslev, Eva ^e   Jiang, Shan ^c   O'Malley, Frances P ^f,g   Pritchard, Kathleen I ^f,h   Shepherd, Lois E ^c   Bartels, Annette ^a   Brünner, Nils ^a   Nielsen, Torsten O ⁱ  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Copenhagen   (Denmark)

^c Clinical Trials Group   (Canada)

^d Statistical Centre   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF TORONTO   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j NONE   (Denmark)

more..

Author keywords

Breast cancer; HER2; NCIC CTG MA.5; Prediction; TIMP 1; TOP2A

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PROTEIN TOP2A; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC HETEROGENEITY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME;

EID: 84857916102     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1896-1     Document Type: Article

References (28)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
2. Levine MN, Bramwell VH, Pritchard KI et al (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16:2651-2658 (Pubitemid 28363028)
3. Ejlertsen B, Mouridsen HT, Jensen MB et al (2007) Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 43:877-884 (Pubitemid 46394520)
4. Carpenter JT, Velez-Garcia E, Aron BS et al (1991) Five year results of a adjuvant comparison of cyclophosphamide, doxorubicin and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil for node positive breast cancer. Proc Am Soc Clin Oncol 13:66 abstr 68
5. Martin M, Villar A, Sole-Calvo A et al (2003) Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 14:833-842 (Pubitemid 36827198)
6. Hutchins LF, Green SJ, Ravdin PM et al (2005) Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23:8313-8321
7. Pritchard KI, Shepherd LE, O'Malley FP et al (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111 (Pubitemid 43736610)
8. Pritchard KI, Messersmith H, Elavathil L et al (2008) HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26:736-744 (Pubitemid 351264386)
9. Paik S, Bryant J, Tan-Chiu E (2000) HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991-1998 (Pubitemid 32045895)
10. Kellner U, Sehested M, Jensen PB et al (2002) Culprit and victim - DNA topoisomerase II. Lancet Oncol 3:235-243 (Pubitemid 34436660)
11. Knoop AS, Knudsen H, Balslev E et al (2005) Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil. J Clin Oncol 23:7483-7490 (Pubitemid 46291811)
12. O'Malley FP, Chia S, Tu D et al (2009) Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101:644-650
13. Ejlertsen B, Jensen MB, Nielsen KV et al (2010) HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 28:984-990
14. Bartlett JM, Munro AF, Dunn JA et al (2010) Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 11:266-274
15. Dhesy-Thind B, Pritchard KI, Messersmith H et al (2008) HER2/ neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 109:209-229 (Pubitemid 351644854)
16. Leo AD, Desmedt C, Bartlett JM et al., HER2/TOP2A Meta-analysis Study Group (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 12:1134-1142
17. Press MF, Sauter G, Buyse M et al (2011) Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 29:859-867
18. Guedez L, Stetler-Stevenson WG, Wolff L et al (1998) In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases- 1. Clin Invest 102:2002-2010 (Pubitemid 29001847)
19. Bigelow RL, Williams BJ, Carroll JL et al (2009) TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro. Breast Cancer Res Treat 117:31-44
20. Li G, Fridman R, Kim HR et al (1999) Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59:6267-6275 (Pubitemid 30035652)
21. Davidsen ML, Würtz SØ, Rømer MU et al (2006) TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 95:1114-1120 (Pubitemid 44606841)
22. Fu ZY, Lv JH, Ma CY et al (2011) Tissue inhibitor of metallo-proteinase- 1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/ NF-κB pathway. Biomed Pharmacother 65:163-167
23. Schrohl AS, Look MP, Meijer-van Gelder ME et al (2009) Tumor tissue levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: a retrospective study. BMC Cancer 9:322
24. Willemoe GL, Hertel PB, Bartels A et al (2009) Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n = 647) with primary breast cancer. Eur J Cancer 45:2528-2536
25. Simon RM, Paik S, Hayes DF et al (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452
26. McShane LM, Altman DG, Sauerbrei W et al (2005) Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072
27. Levine MN, Pritchard KI, Bramwell VH et al (2005) Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23:5166-5170 (Pubitemid 46224025)
28. Sorensen IV, Fenger C, Winther H et al (2006) Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 54:1075-1086 (Pubitemid 44434711)